Andere Sprachen INmune Bio, Inc.

Aktien

A2PCBU

US45782T1051

INMB

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
10.84 ^USD	+2.07%		+23.18%	-3.73%

23.04.	Inmune Bio Inc. kündigt 24-monatige Stabilitätsvalidierung von Xpro? für die Vorbereitung der Phase III und die Modellierung der kommerziellen Lieferkette sowie die Entwicklung eines neuartigen Immunogenitätstests an	CI
08.04.	INmune Bio Inc. präsentiert auf dem AACR 2024 Daten über die Rolle von INB03 als Immun-Checkpoint-Modulator bei der Behandlung von Hochrisiko-Brustkrebs	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	25.04.
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	25.04.
INmune Bio Inc. Announces 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling and Development of Novel Immunogenicity Assay	24.04.
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering	23.04.
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay	23.04.
Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro? for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay	23.04.
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering	22.04.
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024	08.04.
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024	08.04.
INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024	08.04.
INmune Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update	28.03.
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28	26.03.
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy	13.03.
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy	13.03.
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™	05.03.
INmune Bio, Inc. Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro	05.03.
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	12.02.
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024	06.02.
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024	06.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen INmune Bio, Inc.

Aktien

A2PCBU

US45782T1051

INMB

Andere Sprachen

Filter